In Brief: The Medicines Company Hirulog
Executive Summary
NDA submitted Dec 23 and accepted by FDA Feb. 16 for anticoagulant bivalirudin for patients with unstable angina undergoing percutaneous transluminal coronary angioplasy. The company licensed Hirulog from Biogen in 1977 ("The Pink Sheet" March 31, 1997, T&G-13)...
NDA submitted Dec 23 and accepted by FDA Feb. 16 for anticoagulant bivalirudin for patients with unstable angina undergoing percutaneous transluminal coronary angioplasy. The company licensed Hirulog from Biogen in 1977 ("The Pink Sheet" March 31, 1997, T&G-13).... |